GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhenomeX Inc (NAS:CELL) » Definitions » Altman Z-Score

PhenomeX (PhenomeX) Altman Z-Score : -4.03 (As of Apr. 28, 2024)


View and export this data going back to 2020. Start your Free Trial

What is PhenomeX Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -4.03 is in distress zone. This implies bankruptcy possibility in the next two years.

PhenomeX has a Altman Z-Score of -4.03, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for PhenomeX's Altman Z-Score or its related term are showing as below:

CELL' s Altman Z-Score Range Over the Past 10 Years
Min: -4.48   Med: 5.52   Max: 62.87
Current: -4.03

During the past 5 years, PhenomeX's highest Altman Z-Score was 62.87. The lowest was -4.48. And the median was 5.52.


PhenomeX Altman Z-Score Historical Data

The historical data trend for PhenomeX's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhenomeX Altman Z-Score Chart

PhenomeX Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Altman Z-Score
- - 62.87 8.36 -1.23

PhenomeX Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 -0.54 -1.23 -1.81 -4.48

Competitive Comparison of PhenomeX's Altman Z-Score

For the Biotechnology subindustry, PhenomeX's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhenomeX's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhenomeX's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where PhenomeX's Altman Z-Score falls into.



PhenomeX Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

PhenomeX's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.2947+1.4*-2.441+3.3*-0.6836+0.6*1.4734+1.0*0.4027
=-4.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Jun. 2023:
Total Assets was $178.33 Mil.
Total Current Assets was $94.79 Mil.
Total Current Liabilities was $42.23 Mil.
Retained Earnings was $-435.31 Mil.
Pre-Tax Income was -50.194 + -23.399 + -29.247 + -21.544 = $-124.38 Mil.
Interest Expense was -1.632 + -0.384 + -0.23 + -0.229 = $-2.48 Mil.
Revenue was 14.062 + 18.516 + 17.841 + 21.398 = $71.82 Mil.
Market Cap (Today) was $98.79 Mil.
Total Liabilities was $67.05 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(94.786 - 42.225)/178.332
=0.2947

X2=Retained Earnings/Total Assets
=-435.312/178.332
=-2.441

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-124.384 - -2.475)/178.332
=-0.6836

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=98.794/67.051
=1.4734

X5=Revenue/Total Assets
=71.817/178.332
=0.4027

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

PhenomeX has a Altman Z-Score of -4.03 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


PhenomeX  (NAS:CELL) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


PhenomeX Altman Z-Score Related Terms

Thank you for viewing the detailed overview of PhenomeX's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PhenomeX (PhenomeX) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 320, Emeryville, CA, USA, 94608
PhenomeX Inc is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes.
Executives
Siddhartha Kadia director, officer: Chief Executive Officer 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Mehul Joshi officer: Chief Financial Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Peter Silvester director C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
John R Chiminski director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bird Mergersub Corp 10 percent owner 40 MANNING ROAD, BILLERICA MA 01821
Bruker Corp 10 percent owner 40 MANNING RD, BILLERICA MA 01821
James Paul Mcclaskey officer: SVP, Chief Accounting Officer C/O BERKELEY LIGHTS, INC., C/O BERKELEY LIGHTS, INC., EMERYVILLE CA 94608
Scott David Chaplin officer: Chief Legal Officer 3101 WILSON BOULEVARD, SUITE 700, ARLINGTON VA 22201
Eric Hobbs director, officer: Chief Executive Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
James Rothman director 135 EAST 83RD STREET, APT. 15C, NEW YORK NY 10028
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Keith Breinlinger officer: Chief Technical Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Igor Y Khandros director, 10 percent owner 25 HACIENDAS ROAD, ORINDA CA 94563
Stuart L Merkadeau officer: General Counsel 7005 SOUTHFRONT ROAD, LIVERMORE CA 94551